H
epatopulmonary syndrome (HPS) is characterized by a triad of liver disease, hypoxemia, and intrapulmonary vascular dilations (IPVDs). 1 Its prevalence is 4% to 47% in patients with cirrhosis.
1,2 Patients with HPS demonstrate a significant reduction in exercise capacity due to abnormal pulmonary circulation. Anatomic arteriovenous shunts in the lung are used during exercise and lead to exercise-induced impairment in gas exchange and exercise-induced arterial hypoxemia.
The pathogenesis of HPS is unclear. Cytokinemediated injury is alleged to play a key role. Endothelin-1 and tumor necrosis factor (TNF) interaction, occurring in the lung vasculature, contribute to the development of experimental HPS. 3 Overproduction of TNF, due to endotoxin stimulation of Kupffer cells, might be a major mechanism leading to HPS. 4, 5 Pentoxifylline, a nonspecific phosphodiesterase-4 inhibitor, blocks TNF synthesis 6, 7 and TNF-induced macrophagic nitric oxide production. [7] [8] [9] [10] Pentoxifylline prevented the development of HPS 11 and attenuated HPS 12 in cirrhotic rats. However, to our knowledge, pentoxifylline has not been used clinically for the treatment of HPS. In this study, we tried pentoxifylline therapy in patients with HPS.
Methods. Patients.
This was an open-label, prospective, nonrandomized clinical trial to study the efficacy and safety of pentoxifylline therapy for HPS. A consecutive series of patients with cirrhosis attending our hospital were screened. Hepatopulmonary syndrome was diagnosed according to the European Respiratory Society Task Force criteria of PaO 2 less than 80 mm Hg plus positive contrast-enhanced echocardiography (CEE). 1 Subclinical HPS was diagnosed when CEE was positive but PaO 2 was 80 to 90 mm Hg (to convert to kilopascals, multiply by 0.133). Patients with intrinsic cardiopulmonary disease, hepatic encephalopathy, and malignant neoplasms were excluded. The study was approved by an institutional ethics committee, and informed consent was obtained from each patient before enrollment.
Pentoxifylline Treatment. Pentoxifylline was given in a dosage of 400 mg, 3 times daily for 3 months. Patients were monitored for any adverse effects.
Investigations. Cirrhosis was diagnosed by clinical, biochemical, histological, or imaging studies. Viral serologic and other tests were performed to find the cause. Upper gastrointestinal endoscopy and hepatic venous pressure gradient measurements were performed to assess portal hypertension. Chest radiography and pulmonary function tests were performed to exclude chest diseases.
Contrast-enhanced echocardiography was performed with 10 mL of agitated isotonic sodium chloride solution injected in the antecubital vein. The appearance of air bubbles in the left side of the heart after the third beat following the initial appearance in the right side of the heart was considered a positive test result (CEE The frequency of patients having exercise-induced arterial hypoxemia was also determined.
Pretherapy and posttherapy serum TNF levels were determined using commercially available enzymelinked immunosorbent assay kits (Anogen, Mississauga, Ontario, Canada).
Response to Therapy. Response to pentoxifylline therapy, assessed at 3 months, was defined as the following 13 : v Primary end point: Achievement of complete response at 3 months of therapy.
v Secondary end points: Development of serious adverse effects leading to withdrawal of the drug or death from any cause.
Statistical Analysis. For comparison of parameters pretherapy and posttherapy, the Wilcoxon signed rank test was used. PϽ .05 was considered significant. SPSS version 15.0 statistical software (SPSS Inc, Chicago, Illinois) was used for analysis.
Results. Patients.
A total of 251 patients with cirrhosis were screened for the presence of HPS from April 2005 through September 2006. Seventeen patients were excluded because 9 had hepatic encephalopathy, 4 had he-patocellular carcinoma, 3 had pleural effusion, and 1 had rheumatic heart disease. Of the remaining 234 patients, 71 (30%) were CEE ϩ . Of these, 21 patients had HPS and 50 had subclinical HPS. Of 21 patients with HPS, 9 could be included in the trial. Twelve patients could not participate because 5 died before inclusion, 4 refused to participate, and 3 were lost to follow-up before inclusion. The baseline clinical and laboratory characteristics of included patients are given in Table 1 .
Response to Pentoxifylline. CLINICAL. Pretherapy clubbing was seen in all 9 patients (100%), dyspnea and cyanosis were found in 8 patients (89%), palmar erythema was found in 5 patients (56%), and platypnea was found in 3 patients (33%). All 9 patients completed 3 months of therapy. Clinically, there was moderate to marked improvement in dyspnea, cyanosis, and palmar erythema in 8 of 9 patients (89%). Platypnea improved in all 3 patients. One patient (11%) did not show any improvement in any symptoms and signs. PAO 2 LEVELS. There were 8 complete responders (89%) and 1 nonresponder (11%) to therapy. The median baseline PaO 2 levels (ranges) were 73 (54-74) mm Hg with patients in the supine position, 68 (48-72) mm Hg while standing, and 60 (35-65) mm Hg after exercise ( Figure 1 ).
At baseline, 7 of 9 patients (78%) had orthodeoxia, and after therapy, orthodeoxia resolved in 3 of these 7 patients (43%).
The individual EICBO values in patients are shown in Figure 2 . The median (range) pretherapy EICBO was −13.9% (−29.7% to −7.1%), which increased to −7.5% (−27.4% to 5.9%) after therapy (P =.01). Before therapy, all patients had exercise-induced arterial hypoxemia. However, after therapy, only 6 had exercise-induced arterial hypoxemia (P =.21).
TNF LEVELS. After completing 3 months of therapy, the median (range) TNF levels decreased significantly (19.8 [5.5-39.6 ] pg/mL vs 14.5 [5.1-27.9] pg/mL) (P=.02) ( Table 2 and Figure 3) . ADVERSE EFFECTS. Three patients developed transient vomiting, and 2 reported dyspeptic symptoms after pentoxifylline treatment. These subsided with symptomatic treatment. There were no severe adverse effects. There were no significant changes in liver function tests due to treatment with pentoxifylline.
Comment. Our results demonstrate that in patients with HPS, 3 months of treatment with pentoxifylline achieves a significant therapeutic response, with improvement in symptoms and signs in approximately 90% of patients. Furthermore, the exercise tolerance of patients improved, as indicated by an increase in EICBO and reversal of exercise-induced arterial hypoxemia.
The clinical features of HPS typically involve respiratory complaints including cyanosis, dyspnea, platypnea, orthodeoxia (fall in PaO 2 Ն5% or Ն4 mm Hg while standing), and clubbing.
1 Diagnosis of HPS is based on arterial deoxygenation and CEE ϩ in the absence of intrinsic cardiopulmonary disease. 1 We used this criterion to diagnose HPS.
Liver transplantation is the only established effective therapy for HPS.
14 However, mortality is increased after transplantation in patients who have HPS, and transplantation is not uniformly effective in reversing HPS. 14, 15 To our knowledge, there is currently no effective medical therapy for HPS. Small uncontrolled studies have reported a lack of efficacy with the use of sympathomimetics, somatostatin, almitrine, indomethacin, and plasma exchange.
1 Reports using garlic, 13, 16 aspirin, 17 and nitric oxide inhibitor 18, 19 showed variable results. These reports underscore the need to evaluate agents targeting pathogenetic mechanisms of HPS to determine efficacy.
The overproduction of nitric oxide in lungs of patients with cirrhosis is ascribable to intravascular macrophage induction of inducible nitric oxide synthase, which accumulates in the pulmonary vasculature. 20 Since TNF is a potent inducible nitric oxide synthase activator in macrophages, TNF inhibition might prevent pulmonary nitric oxide overproduction, 9 thereby preventing or attenuating HPS. Pentoxifylline blocks TNF synthesis 6, 7 and TNF-induced macrophagic production.
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Sztrymf et al 11 have shown that inhibition of TNF with pentoxifylline in cirrhotic rats prevents development of hyperdynamic circulatory state and HPS. Moreover, pentoxifylline attenuated experimental HPS. 12 The results of the present study show a very encouraging response to pentoxifylline therapy in patients with HPS, and the improvement in symptoms and PaO 2 provides proof of principle.
Pentoxifylline also improved exercise tolerance. Before therapy, all patients had a decrease in their blood oxygen content during exercise, with a median EICBO of −13.9%. With treatment, the median EICBO significantly increased to −7.5%. Moreover, exercise-induced arterial hypoxemia reversed in 3 patients.
In animal studies, 11, 12 the dosage of pentoxifylline used was 10 to 50 mg/kg/d. We used 400 mg, 3 times daily (approximately 20 mg/kg/d), which is the dosage currently approved by the Food and Drug Administration. A proper dose-finding study would be needed to determine the optimum dose for use in HPS. The adverse effects of pentoxifylline were few, nonserious, and easily manageable and did not require drug withdrawal.
There were a few limitations in our study. First, we did not have a control group of patients for TNF levels, ie, cirrhotic patients without HPS. Our assumption that TNF levels are high in cirrhotic patients with HPS compared with cirrhotic patients without HPS was based on previous animal studies. 5 Moreover, with pentoxifylline therapy, improvement in HPS symptoms correlated with a decrease in TNF levels. Second, we had only 9 patients in our study. Classic HPS is rare, while subclinical HPS is more common. In a period of 18 months, only 21 pa- tients fit the criteria for HPS, while we found 50 patients with subclinical HPS. Third, this was an openlabel trial without any comparator group receiving placebo. Although recommendations cannot be formed based on this open-label pilot study of just 9 patients, larger randomized controlled trials can be initiated based on the encouraging results of the present study.
In conclusion, our results suggest that pentoxifylline can be considered a safe and effective therapy for HPS. Further trials should address the issues of using higher dosage, longer duration, and combination with other drugs and whether its use can prevent progression of subclinical HPS.
